Zibotentan/Dapagliflozin + Dapagliflozin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Kidney Disease With High Proteinuria
Conditions
Chronic Kidney Disease With High Proteinuria
Trial Timeline
May 7, 2025 → Jul 31, 2026
NCT ID
NCT06942910About Zibotentan/Dapagliflozin + Dapagliflozin
Zibotentan/Dapagliflozin + Dapagliflozin is a phase 2 stage product being developed by AstraZeneca for Chronic Kidney Disease With High Proteinuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06942910. Target conditions include Chronic Kidney Disease With High Proteinuria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06942910 | Phase 2 | Recruiting |
| NCT06087835 | Phase 3 | Active |
Competing Products
20 competing products in Chronic Kidney Disease With High Proteinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |